About Pentacel® & Quadracel®

Vaccine Antigens

Vaccination Schedule

For US Health Care Professionals

Please see full Important Safety Information for Pentacel and Quadracel below.
Please see full Prescribing Information for Pentacel (49281-0510-05
and 49281-0511-05) and Quadracel.
Medical Information
Order Now

For US Health Care Professionals

Please see full Important Safety Information for Pentacel and Quadracel below.
Please see full Prescribing Information for
Pentacel (49281-0510-05
and 49281-0511-05)
and Quadracel.
Medical Information
Order Now
Overview Choose a Section
Start Strong, Finish Strong
Schedule for children from 2 months to 6 years For children at 2 months, 4 months, 6 months, 15-18 months and 4-6 years

Start your primary DTaP immunization series in children 6 weeks through 4 years of age (prior to 5th birthday) with 4 doses of Pentacel, the only DTaP-IPVb-Hibc combination. Finish the DTaP series with Quadracel as the 5th dose in children 4 through 6 years of age.1,2

Completing the series with Pentacel and Quadracel reduces the number of injections as compared with single-entity vaccines. By using Quadracel, it satisfies the ACIP’sd 5-dose DTaP recommendation with full antigen continuity.1-4

Completing the series with Pentacel and Quadracel reduces the number of injections as compared with single-entity vaccines. By using Quadracel, it satisfies the ACIP’sd 5-dose DTaP recommendation with full antigen continuity.1-4

INDICATION FOR PENTACEL AND QUADRACEL

Pentacel is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to H influenzae type b. Pentacel is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).

Quadracel is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel vaccine and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).

It Takes Two:
Pentacel & Quadracel

Pentacel icon

The only Hib-containing DTaP-IPV
combination vaccine with a
4-dose indication1

Quadracel icon

The same liquid DTaP-IPV component as
in Pentacel1,2

Antigens

DTaP-IPV/Hib1

DTaP-IPV2

Schedule

Doses at 2, 4, 6, and 15-18 months1,3

A dose at 4-6 years2,3

Young boy with his hands on his hips

CONTINUITY OF ANTIGENS
across the entire childhood DTaP and IPV series1-3,5

Pentacel blue block number 1
Pentacel blue block number 2
Pentacel blue block number 3
Pentacel blue block number 4
bracket under Pentacel blue blocks
Pentacel icon
baby
Quadracel purple block number 5
bracket under Quadracel purple blocks
Quadracel icon

Pentacel and Quadracel may simplify vaccine administration by supporting
A VACCINATION SCHEDULE
WITH FEWER INJECTIONS1-4
compared to single-entity alternatives

Centers for Disease Control and Prevention schedule through 6 years of age3
IMPACT OF PENTACEL AND QUADRACEL1-3
POTENTIAL SHOT
SAVINGS1-3
WITHOUT PENTACEL AND QUADRACEL1-3
Vaccine Age
Hepatitis B Hep B
Diphtheria, tetanus, pertussis DTaP
Inactivated poliovirus Polio
Haemophilus influenzae type b Hib
Rotavirus RV
Pneumococcal conjugate PCV
Influenza (2 doses for some) Flu (2 doses for some)
Measles, mumps, rubella MMR
Varicella Varicella
Hepatitis A Hep A
Meningococcal MenACWY
Pneumococcal polysaccharide PPSV

Birth Birth		 1
Month 1
Mo.		 2
Months 2
Mos.		 4
Months 4
Mos.		 6
Months 6
Mos.		 12
Months 12
Mos.		 15
Months 15
Mos.		 18
Months 18
Mos.		 19-23
Months 19-23
Mos.		 2-3
Years 2-3
Yrs.		 4-6
Years 4-6
Yrs.
Hep B Hep B Hep B
DTaP DTaP DTaP DTaP DTaP
IPV IPV IPV IPV
Hib Hib Hib Hib Hib
RV RV RVe
PCV PCV PCV PCV PCV
Influenza (yearly)
MMRf MMR MMR
Varicella Varicella
Hep A (2-dose series) Hep A (2-dose series)
MenACWY
PPSV

Birth Birth		 1
Month 1
Mo.		 2
Months 2
Mos.		 4
Months 4
Mos.		 6
Months 6
Mos.		 12
Months 12
Mos.		 15
Months 15
Mos.		 18
Months 18
Mos.		 19-23
Months 19-23
Mos.		 2-3
Years 2-3
Yrs.		 4-6
Years 4-6
Yrs.
Hep B Hep B Hep B
Hib
RV RV RVe
PCV PCV PCV PCV PCV
Influenza (yearly)
MMRf MMR MMR
Varicella Varicella
Hep A (2-dose series) Hep A (2-dose series)
MenACWY
PPSV

Birth Birth		 1
Month 1
Mo.		 2
Months 2
Mos.		 4
Months 4
Mos.		 6
Months 6
Mos.		 12
Months 12
Mos.		 15
Months 15
Mos.		 18
Months 18
Mos.		 19-23
Months 19-23
Mos.		 2-3
Years 2-3
Yrs.		 4-6
Years 4-6
Yrs.
Hep B Hep B Hep B
Hib
RV RV RVe
PCV PCV PCV PCV PCV
Influenza (yearly)
MMRf MMR MMR
Varicella Varicella
Hep A (2-dose series) Hep A (2-dose series)
MenACWY
PPSV

RV = Respiratory syncytial virus. PCV = Pneumococcal conjugate vaccine. MMR = Measles, mumps, and rubella.

Range of recommended ages for all children

Range of recommended ages for certain high-risk groups

Adapted from: Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021.

Vaccination schedules may vary based on patients’ overall health status.3

eDepending on the type of vaccine used, a 3rd dose may be required.

fFor certain high-risk groups, a dose at 6-11 months of age is recommended.

Download Immunization Schedule
With Pentacel and Quadracel

Pentacel
Reconstitution Video
baby on stomach with a bow

“USE COMBINATION VACCINES
INSTEAD OF SEPARATE INJECTIONS
WHEN APPROPRIATE.”
– Advisory Committee on Immunization Practices, 20213
By using these two combination vaccines as directed,
your office could:

Blue and purple pill bottle icons

Help minimize the
number of injections

Pentacel & Quadracel allow you to use only 2 products across the entire childhood series for DTaP, IPV, and Hib.1-4

Help improve timeliness of vaccination coverage

Combination vaccines may help increase timeliness of vaccination administration and coverage.4,6,7

Doctor icon with check mark
Bar graph icon

Help streamline inventory, billing, and administration prep time4

COMPLETE THE DTaP, IPV, AND Hib SERIES
FROM START TO FINISH
Provide CDC-recommended DTaP, IPV, and Hib immunizations
with Pentacel & Quadracel1-3

Thermometer icon

Most common
adverse reactions

The most common local and systemic adverse reactions to Pentacel include erythema, swelling, and tenderness at the injection site; fever; fussiness; and abnormal crying. The most common local and systemic adverse reactions to Quadracel include pain, erythema, and edema at the injection site; myalgia; malaise; and headache.1,2

One less injection

By using Quadracel, a combination booster dose, you can complete the DTaP and IPV immunization series with one less injection and fewer vaccines to store in your refrigerator compared to single-entity alternatives.2,3

Downward arrow
Bottle icon for 5th dose

Antigen continuity

Using Quadracel, you can have continuity of DTaP and IPV antigens across the 5-dose series1-3,5

Important Safety Information for Pentacel and Quadracel

Contraindications to vaccination with Pentacel or Quadracel vaccine include: a severe allergic reaction (e.g., anaphylaxis) to any ingredient of the vaccine, or following any other diphtheria toxoid-, tetanus toxoid-, pertussis antigen-containing vaccine, inactivated poliovirus vaccine, or Haemophilus influenzae type b vaccine (Pentacel only); encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause; or a progressive neurologic disorder.

Important Safety Information for Pentacel and Quadracel

Contraindications to vaccination with Pentacel or Quadracel include: a severe allergic reaction (e.g., anaphylaxis) to any ingredient of the vaccine, or following any other diphtheria toxoid-, tetanus toxoid-, pertussis antigen-containing vaccine, inactivated poliovirus vaccine, or Haemophilus influenzae type b vaccine (Pentacel only); encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause; or a progressive neurologic disorder.

Carefully consider benefits and risks before administering Pentacel or Quadracel to persons with a history of: fever ≥105°F, hypotonic-hyporesponsive episode, or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis antigen-containing vaccine; seizures within 3 days after a previous pertussis antigen-containing vaccine; Guillain-Barré syndrome occurring within 6 weeks following receipt of a prior vaccine containing tetanus toxoid; or adverse events after a previous dose of Pentacel or Quadracel or receipt of any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine.

For infants and children with a history of previous seizures, an antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with Pentacel and for the next 24 hours.

Apnea following intramuscular vaccination has been observed in some infants born prematurely.

The most common local and systemic adverse reactions to Pentacel include erythema, swelling, and tenderness at the injection site; fever, fussiness, and abnormal crying. The most common local and systemic adverse reactions to Quadracel include pain, erythema, and edema at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur.

Vaccination with Pentacel or Quadracel may not protect all individuals.

Before administration, please see the full Prescribing Information for Pentacel (49281-0510-05 and 49281-0511-05) and Quadracel.

CPT®o Code for Pentacel: 90698

CPT Code for Quadracel: 90696

Pentacel is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA, and distributed by Sanofi Pasteur Inc.

Quadracel is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.

aDTaP = Diphtheria, tetanus, and acellular pertussis.

bIPV = Inactivated poliovirus.

cHib = Haemophilus influenzae type b.

dACIP = Advisory Committee on Immunization Practices.

eDepending on the type of vaccine used, a 3rd dose may be required.

fFor certain high-risk groups, a dose at 6-11 months of age is recommended.

gAny: Mild, Moderate or Severe.

hFever is based upon actual temperatures recorded with no adjustments to the measurement route.

iDAPTACEL (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).

jIPOL (Poliovirus Vaccine Inactivated).

kActHIB (Haemophilus b Conjugate Vaccine [Tetanus Toxoid Conjugate]).

lGrade 1: >0 to <25 mm increase over pre-vaccination measurement; Grade 2: ≥25 to ≤50 mm increase over pre-vaccination measurement; Grade 3: >50 mm increase over pre-vaccination measurement.

mSwelling of the injected limb including the adjacent joint (ie, elbow and/or shoulder) as compared to baseline.

nGrade 1: No interference with activity; Grade 2: Some interference with activity; Grade 3: Significant; prevents daily activity.

oCPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.

References:
  • Pentacel [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.
  • Quadracel [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.
  • Centers for Disease Control and Prevention (CDC). Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2021. Accessed May 21, 2021. https://www.cdc.gov/vaccines/schedules/
    downloads/child/0-18yrs-child-combined-schedule.pdf
  • Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. May 4, 2021. Accessed August 31, 2021. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf.
  • Liang J, Wallace G, Mootrey G. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR. 2015;64(34):948-949.
  • Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):507-512.
  • Marshall GS, Happe LE, Lunacsek OE, et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496-500.
Sanofi Pasteur logo
This site is intended for US Health Care Professionals.
© 2021 Sanofi Pasteur Inc.
Last Modified 12/2021
MAT-US-2006087-v3.0-12/2021
x

Please see full Prescribing Information for Pentacel (49281-0510-05 and 49281-0511-05).